KR102676822B1 - Atr 키나아제의 헤테로시클릭 저해제 - Google Patents

Atr 키나아제의 헤테로시클릭 저해제 Download PDF

Info

Publication number
KR102676822B1
KR102676822B1 KR1020207004080A KR20207004080A KR102676822B1 KR 102676822 B1 KR102676822 B1 KR 102676822B1 KR 1020207004080 A KR1020207004080 A KR 1020207004080A KR 20207004080 A KR20207004080 A KR 20207004080A KR 102676822 B1 KR102676822 B1 KR 102676822B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
cycloalkyl
salt
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207004080A
Other languages
English (en)
Korean (ko)
Other versions
KR20200028441A (ko
Inventor
프란체스코 마리아 에밀리아 디
필립 존스
크리스토퍼 로렌스 캐롤
제이슨 브라이언트 크로스
수얌부 케사바 비자얀 라마스와미
마이클 개럿 존슨
사라 라이블리
데이비드 라포인트
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
켐파트너 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템, 켐파트너 코포레이션 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Publication of KR20200028441A publication Critical patent/KR20200028441A/ko
Application granted granted Critical
Publication of KR102676822B1 publication Critical patent/KR102676822B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207004080A 2017-07-13 2018-07-13 Atr 키나아제의 헤테로시클릭 저해제 Active KR102676822B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531951P 2017-07-13 2017-07-13
US62/531,951 2017-07-13
PCT/US2018/042128 WO2019014618A1 (en) 2017-07-13 2018-07-13 HETEROCYCLIC INHIBITORS OF KINASE ATR

Publications (2)

Publication Number Publication Date
KR20200028441A KR20200028441A (ko) 2020-03-16
KR102676822B1 true KR102676822B1 (ko) 2024-06-19

Family

ID=64998660

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207004080A Active KR102676822B1 (ko) 2017-07-13 2018-07-13 Atr 키나아제의 헤테로시클릭 저해제

Country Status (23)

Country Link
US (3) US10392376B2 (https=)
EP (1) EP3651768B1 (https=)
JP (1) JP7159307B2 (https=)
KR (1) KR102676822B1 (https=)
CN (2) CN117466884A (https=)
AU (1) AU2018301696B8 (https=)
CA (1) CA3069693A1 (https=)
DK (1) DK3651768T3 (https=)
ES (1) ES2974334T3 (https=)
FI (1) FI3651768T3 (https=)
HR (1) HRP20240368T1 (https=)
HU (1) HUE066043T2 (https=)
IL (1) IL271930B (https=)
LT (1) LT3651768T (https=)
MX (1) MX2020000386A (https=)
PH (1) PH12020500072A1 (https=)
PL (1) PL3651768T3 (https=)
PT (1) PT3651768T (https=)
RS (1) RS65466B1 (https=)
SI (1) SI3651768T1 (https=)
SM (1) SMT202400106T1 (https=)
WO (1) WO2019014618A1 (https=)
ZA (1) ZA202000148B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
US10377591B2 (en) 2017-07-07 2019-08-13 Zebra Technologies Corporation Input handling for media processing devices
HUE066043T2 (hu) * 2017-07-13 2024-07-28 Univ Texas A TR kináz beterociklusos inhibitorai
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム Atrキナーゼの複素環式阻害剤
CN111655688B (zh) * 2017-09-08 2023-09-29 蓝谷制药有限责任公司 经取代的吡咯并吡啶类化合物作为atr抑制剂
JP7341156B2 (ja) * 2018-03-16 2023-09-08 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム Atrキナーゼの複素環式阻害剤
TW202028209A (zh) * 2018-09-27 2020-08-01 大陸商重慶複創醫藥研究有限公司 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物
CN118619944A (zh) * 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN113121524B (zh) * 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
EP4159734B1 (en) 2020-05-29 2025-08-13 Wuxi Life Fountain Biotech Co., Ltd. Fluoropyrrolopyridine compound and application thereof
MX2023000198A (es) * 2020-07-03 2023-02-22 Antengene Discovery Ltd Inhibidores de atr y usos de estos.
WO2022171034A1 (zh) * 2021-02-10 2022-08-18 江苏先声药业有限公司 作为hpk1抑制剂的双环类化合物及其应用
IL308409A (en) * 2021-05-12 2024-01-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd Sulfoximine-containing atr inhibitor compound
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007080382A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
US20160287604A1 (en) 2014-08-04 2016-10-06 Bayer Pharma Aktiengesellschaft 2-(morpholin-4-yl)-1,7-naphthyridines

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001265871A1 (en) * 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US7550470B2 (en) * 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
GB0501999D0 (en) * 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
MX2009002046A (es) 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
WO2008032072A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
JP2008115166A (ja) * 2006-10-10 2008-05-22 Daiichi Sankyo Co Ltd ピリジルフェニルメチルスルホン誘導体
WO2008125833A1 (en) 2007-04-12 2008-10-23 Piramed Limited Pharmaceutical compounds
US20080292588A1 (en) 2007-05-17 2008-11-27 Anadys Pharmaceuticals, Inc. 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives
EP2178866A2 (en) * 2007-07-09 2010-04-28 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2009007751A2 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CA2692945A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Compounds - 945
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
CN102143746A (zh) 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
KR20170015566A (ko) * 2008-11-10 2017-02-08 버텍스 파마슈티칼스 인코포레이티드 Atr 키나제의 억제제로서 유용한 화합물
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
WO2010120996A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2011106276A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
JP2013526539A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用なピラジン
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
DK3077397T3 (da) 2013-12-06 2019-12-16 Vertex Pharma 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク LRRK2阻害薬としての新規の3,4−二置換−1H−ピロロ[2,3−b]ピリジンおよび4,5−二置換−7H−ピロロ[2,3−c]ピリダジン
PL3152212T3 (pl) 2014-06-05 2020-06-15 Vertex Pharmaceuticals Inc. Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
KR102569226B1 (ko) 2014-10-13 2023-08-22 아트린 파마슈티컬스 엘엘씨 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
HUE066043T2 (hu) 2017-07-13 2024-07-28 Univ Texas A TR kináz beterociklusos inhibitorai
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム Atrキナーゼの複素環式阻害剤
JP7341156B2 (ja) 2018-03-16 2023-09-08 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム Atrキナーゼの複素環式阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007080382A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
US20160287604A1 (en) 2014-08-04 2016-10-06 Bayer Pharma Aktiengesellschaft 2-(morpholin-4-yl)-1,7-naphthyridines

Also Published As

Publication number Publication date
IL271930A (en) 2020-02-27
CN111867590B (zh) 2023-11-17
HRP20240368T1 (hr) 2024-08-30
JP7159307B2 (ja) 2022-10-24
JP2020527174A (ja) 2020-09-03
HUE066043T2 (hu) 2024-07-28
US20210047311A1 (en) 2021-02-18
AU2018301696B2 (en) 2022-10-27
NZ761374A (en) 2025-10-31
EP3651768B1 (en) 2023-12-20
CA3069693A1 (en) 2019-01-17
PT3651768T (pt) 2024-03-20
EP3651768A4 (en) 2021-04-07
CN117466884A (zh) 2024-01-30
IL271930B (en) 2022-07-01
US20190016713A1 (en) 2019-01-17
US10392376B2 (en) 2019-08-27
CN111867590A (zh) 2020-10-30
FI3651768T3 (fi) 2024-03-14
RS65466B1 (sr) 2024-05-31
PL3651768T3 (pl) 2024-09-02
KR20200028441A (ko) 2020-03-16
WO2019014618A1 (en) 2019-01-17
SI3651768T1 (sl) 2024-05-31
SMT202400106T1 (it) 2024-05-14
ES2974334T3 (es) 2024-06-26
ZA202000148B (en) 2024-08-28
MX2020000386A (es) 2020-08-06
AU2018301696B8 (en) 2023-03-23
EP3651768A1 (en) 2020-05-20
AU2018301696A8 (en) 2023-03-23
DK3651768T3 (da) 2024-03-18
US20200102296A1 (en) 2020-04-02
AU2018301696A1 (en) 2020-02-27
US11434233B2 (en) 2022-09-06
PH12020500072A1 (en) 2020-11-09
US10800769B2 (en) 2020-10-13
LT3651768T (lt) 2024-04-25

Similar Documents

Publication Publication Date Title
KR102676822B1 (ko) Atr 키나아제의 헤테로시클릭 저해제
JP7290627B2 (ja) Atrキナーゼの複素環式阻害剤
CN112218631B (zh) Atr激酶的杂环抑制剂
US10745420B2 (en) Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
HK40028148B (en) Heterocyclic inhibitors of atr kinase
HK40028148A (en) Heterocyclic inhibitors of atr kinase

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200211

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210705

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230905

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240426

Patent event code: PE09021S01D

Comment text: Notification of reason for refusal

Patent event date: 20230905

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240617

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240617

End annual number: 3

Start annual number: 1

PG1601 Publication of registration